Stocksigma LogoStocksigma Logo

Morepen Laboratories Delivers Record Q2 & H1 FY27 Performance Driven by CDMO Scale-Up

Morepen Laboratories reported strong Q2 FY27 results, with revenue surging 81% YoY to Rs. 755 Cr, EBITDA jumping 273% YoY to Rs

Morepen Laboratories Delivers Record Q2 & H1 FY27 Performance Driven by CDMO Scale-Up

Morepen Laboratories Ltd 路 Investor Presentation 路 27 Oct 2026, 7:13 pm

Morepen Laboratories Delivers Record Q2 & H1 FY27 Performance Driven by CDMO Scale-Up Morepen Laboratories reported strong Q2 FY27 results, with revenue surging 81% YoY to Rs. 755 Cr, EBITDA jumping 273% YoY to Rs. 132 Cr (margin up 897 bps to 17.45%), and PAT rising 117% YoY to Rs. 89 Cr. Growth was powered by CDMO revenues jumping 4.3x QoQ to Rs. 253 Cr, accounting for 52% of API + CDMO sales. For H1 FY27, revenue reached Rs. 1,330 Cr (+57% YoY) and PAT grew 177% YoY to Rs. 145 Cr, while TTM ROCE and ROE expanded to 18.8% and 13.6%.

Original exchange filing (PDF)

More announcements from Morepen Laboratories Ltd

All Morepen Laboratories Ltd announcements